ASSERTIO HOLDINGS INC (ASRT)

US04546C2052 - Common Stock

0.8571  -0.03 (-3.7%)

ASSERTIO HOLDINGS INC

NASDAQ:ASRT (12/23/2024, 12:24:04 PM)

0.8571

-0.03 (-3.7%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%93.48%
Sales Q2Q%-18.03%
CRS12.8
6 Month-22.97%
Overview
Earnings (Last)11-11 2024-11-11/amc
Earnings (Next)N/A N/A
Ins Owners0.95%
Inst Owners38.74%
Market Cap81.84M
Shares95.48M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82
Short Float %5.96%
Short Ratio7.08
IPO02-12 1997-02-12
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ASRT Daily chart

Company Profile

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 53 full-time employees. The firm has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

Company Info

ASSERTIO HOLDINGS INC

100 S. Saunders Road, Suite 300

Lake Forest ILLINOIS 60045

P: 12244197106

CEO: Daniel A. Peisert

Employees: 53

Website: https://www.assertiotx.com/

ASRT News

News Image6 days ago - Assertio Holdings, Inc.Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with...

News Image10 days ago - Assertio Holdings, Inc.Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study

Same-day dosing results comparable to next day dosing schedules...

News Image11 days ago - Assertio Holdings, Inc.Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

CTO Role to Focus on Growth from New Market and Revenue Strategies...

News Image17 days ago - Beam TherapeuticsBeam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
News Imagea month ago - Assertio Holdings, Inc.Assertio Reports Third Quarter 2024 Financial Results

Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million  Cash and Short-Term Investments of $88.6 Million...

News Imagea month ago - Assertio Holdings, Inc.Assertio Provides Response to Letter from Short-seller

Claims about Rolvedon and Assertio’s Accounting Practices are False and Baseless Short-seller’s Press Release is Another Improper Attempt to Enrich...

ASRT Twits

Here you can normally see the latest stock twits on ASRT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example